41
views
0
recommends
+1 Recommend
0 collections
    38
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Original, population-based estimates of indicators of long-term survival and cure in cancer patients are provided. More than a quarter of cancer patients in Italy have reached death rates similar to those of the general population. Nearly three quarters of them will not die as a result of cancer. These estimates are potentially helpful to health-care planners, clinicians, and patients.

          Abstract

          Background

          Persons living after a cancer diagnosis represent 4% of the whole population in high-income countries. The aim of the study was to provide estimates of indicators of long-term survival and cure for 26 cancer types, presently lacking.

          Patients and methods

          Data on 818 902 Italian cancer patients diagnosed at age 15–74 years in 1985–2005 were included. Proportions of patients with the same death rates of the general population (cure fractions) and those of prevalent patients who were not at risk of dying as a result of cancer (cure prevalence) were calculated, using validated mixture cure models, by cancer type, sex, and age group. We also estimated complete prevalence, conditional relative survival (CRS), time to reach 5- and 10-year CRS >95%, and proportion of patients living longer than those thresholds.

          Results

          The cure fractions ranged from >90% for patients aged <45 years with thyroid and testis cancers to <10% for liver and pancreatic cancers of all ages. Five- or 10-year CRS >95% were both reached in <10 years by patients with cancers of the stomach, colon–rectum, pancreas, corpus and cervix uteri, brain, and Hodgkin lymphoma. For breast cancer patients, 5- and 10-year CRSs reached >95% after 19 and 25 years, respectively, and in 15 and 18 years for prostate cancer patients. Five-year CRS remained <95% for >25 years after cancer diagnosis in patients with liver and larynx cancers, non-Hodgkin lymphoma, myeloma, and leukaemia. Overall, the cure prevalence was 67% for men and 77% for women. Therefore, 21% of male and 31% of female patients had already reached 5-year CRS >95%, whereas 18% and 25% had reached 10-year CRS >95%.

          Conclusions

          A quarter of Italian cancer patients can be considered cured. This observation has a high potential impact on health planning, clinical practice, and patients' perspective.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care.

          Cancer survivors represent a growing population, heterogeneous in their need for medical care, psychosocial support, and practical assistance. To inform survivorship research and practice, this manuscript will describe the prevalent population of cancer survivors in terms of overall numbers and prevalence by cancer site and time since diagnosis. Incidence and survival data from 1975-2007 were obtained from the Surveillance, Epidemiology, and End Results Program and population projections from the United States Census Bureau. Cancer prevalence for 2012 and beyond was estimated using the Prevalence Incidence Approach Model, assuming constant future incidence and survival trends but dynamic projections of the U.S. population. As of January 1, 2012, approximately 13.7 million cancer survivors were living in the United States with prevalence projected to approach 18 million by 2022. Sixty-four percent of this population have survived 5 years or more; 40% have survived 10 years or more; and 15% have survived 20 years or more after diagnosis. Over the next decade, the number of people who have lived 5 years or more after their cancer diagnosis is projected to increase approximately 37% to 11.9 million. A coordinated agenda for research and practice is needed to address cancer survivors' long-term medical, psychosocial, and practical needs across the survivorship trajectory. Prevalence estimates for cancer survivors across the survivorship trajectory will inform the national research agenda as well as future projections about the health service needs of this population.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cancer survivors: a booming population.

              In this first article of what is planned to be an annual series, we examine the history of cancer prevalence reporting and the role that these annual figures play in guiding the direction of cancer control research, and specifically the science of cancer survivorship. For this inaugural year, we focus on the confluence of the growing number of survivors and population aging, and the impact these combined trends will have on cancer survivorship in the future. State or metro area-level cancer incidence and prevalence data were collected from 9 registries via the Surveillance, Epidemiology, and End Results Program. The complete prevalence method was used to estimate prevalence for 2008 and the Prevalence, Incidence Approach Model method was used to project prevalence data through 2020, assuming flat cancer incidence and survival trends but dynamic U.S. population projections. As of January 2008, the number of cancer survivors is estimated at 11.9 million. Approximately 60% of cancer survivors are age 65 or older, and by the year 2020, it is estimated that 63% of cancer survivors will be age 65 or older. Improved survival and population aging converge to generate a booming population of older adult cancer survivors, many of whom have multiple complex health conditions and unique survivorship needs. This demographic shift has important implications for future health care needs and costs of the U.S. population. The findings provide information critical for guiding cancer prevention and control research and service provision. ©2011 AACR
                Bookmark

                Author and article information

                Journal
                Ann Oncol
                Ann. Oncol
                annonc
                annonc
                Annals of Oncology
                Oxford University Press
                0923-7534
                1569-8041
                November 2014
                22 August 2014
                22 August 2014
                : 25
                : 11
                : 2251-2260
                Affiliations
                [1 ]Epidemiology and Biostatistics Unit, CRO Aviano National Cancer Institute IRCCS , Aviano
                [2 ]Veneto Tumour Registry, Veneto Region, Padua
                [3 ]AIRTUM Database , Florence
                [4 ]Tuscany Cancer Registry, Clinical and Descriptive Epidemiology Unit, Cancer Prevention and Research Institute (ISPO) , Florence
                [5 ]National Centre for Epidemiology, Surveillance and Health Promotion (CNESPS), Italian National Institute of Health (ISS) , Rome
                [6 ]Department of Oncology, Anatomic Pathology Unit, General Hospital of Treviso , Treviso
                [7 ]Romagna Cancer Registry, Cancer Institute of Romagna (IRCSS) , Meldola
                [8 ]Milan Cancer Registry, Milan Health Authority, Epidemiology Unit, Milan
                [9 ]Umbria Cancer Registry, Department of Medical and Surgical Specialties, and Public Health, Section of Public Health, Perugia University , Perugia
                [10 ]Ferrara Cancer Registry, Ferrara University , Ferrara
                [11 ]Siracusa Cancer Registry, ASP of Siracusa , Siracusa
                [12 ]Medical Oncology Unit, CRO Aviano National Cancer Institute IRCCS , Aviano, Italy
                Author notes
                [* ] Correspondence to: Dr Luigino Dal Maso, Epidemiology and Biostatistics Unit, CRO Aviano National Cancer Institute IRCCS, Via Franco Gallini 2, 33081 Aviano, Italy. Tel: +39-0434-659354; Fax: +39-0434-659231; E-mail: epidemiology@ 123456cro.it
                [†]

                See Members of the AIRTUM Working Group in the Appendix section.

                Article
                mdu383
                10.1093/annonc/mdu383
                4207730
                25149707
                17f4a843-7fbb-4963-85cf-98dd8e98e204
                © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

                History
                : 8 May 2014
                : 4 August 2014
                : 5 August 2014
                Categories
                Original Articles
                Epidemiology

                Oncology & Radiotherapy
                survival,prevalence,cancer cure,italy
                Oncology & Radiotherapy
                survival, prevalence, cancer cure, italy

                Comments

                Comment on this article